Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)

Study:

A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Rationale:

n/a

Purpose:

This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or refractory multiple myeloma.

Study Status: Recruiting

Recruiting:
Becky Habecker 216-445-2612 habeckb@ccf.org

Condition Intervention Phase
Multiple Myeloma Drug: bevacizumab
Drug: placebo
Drug: bortezomib
Phase 2

Verified by Genentech April, 2008

Sponsored by: Genentech
Information provided by: Genentech
ClinicalTrials.gov identifier: NCT00473590

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind (Investigator), Placebo Control, Parallel Assignment

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

Eric Hedrick, M.D.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site